What is the Current Status of the EXPAREL Patent Lawsuit?
Pacira Biosciences is involved in patent litigation concerning its long-acting local anesthetic, EXPAREL (bupivacaine liposome injectable suspension). The primary focus of these disputes is the validity and infringement of patents covering EXPAREL.
When Does EXPAREL's Key Patent Expire?
The patent most central to the EXPAREL litigation is United States Patent No. 9,775,859. This patent is scheduled to expire in 2026. However, patent expirations can be complex, influenced by factors such as patent term extensions and ongoing legal challenges [1].
Why Are Companies Challenging the EXPAREL Patent?
Generic drug manufacturers often challenge patents on branded drugs to pave the way for their own versions to enter the market. In the case of EXPAREL, companies have filed Abbreviated New Drug Applications (ANDAs) and subsequently initiated Paragraph IV litigation. This legal strategy challenges the validity or non-infringement of the patent listed in the FDA’s Orange Book for the branded drug [2].
What Could Happen if the Patent is Found Invalid or Not Infringed?
If a court rules that the '859 patent is invalid or that a generic product does not infringe it, this would remove a significant barrier to the market entry of generic versions of EXPAREL. This scenario could lead to increased competition and potentially lower prices for the anesthetic [2].
How Does EXPAREL Compare to Other Anesthetics?
EXPAREL is a bupivacaine liposome injectable suspension designed for single-dose administration to provide post-operative analgesia for up to 72 hours. It is distinct from traditional local anesthetics, which typically provide pain relief for only a few hours. This prolonged duration of action is a key differentiator for EXPAREL in managing post-surgical pain [3].
Who Are the Potential Competitors for EXPAREL?
The competitive landscape for EXPAREL includes other long-acting local anesthetics and multimodal pain management strategies. Companies seeking to enter the market with generic EXPAREL would become direct competitors. Additionally, other branded or generic drugs and non-pharmacological approaches for pain management also represent indirect competition [3].
What is the Timeline for Generic EXPAREL Entry?
The timeline for generic EXPAREL entry is directly tied to the outcome of the patent litigation and the expiration date of relevant patents. If the '859 patent is successfully challenged or expires without further extensions, generic versions could become available. DrugPatentWatch.com tracks these patent statuses and litigation developments [1].
What Clinical Data is Available for EXPAREL?
EXPAREL's efficacy and safety have been demonstrated in clinical studies for various surgical procedures, including orthopedic surgery, abdominal surgery, and others. The drug is indicated for interscalene brachial plexus block for postoperative shoulder pain and for infiltration into the surgical site for postoperative pain management following open or minimally invasive abdominal procedures [4].
What Patient Concerns Exist Regarding Pain Management?
Patients often have concerns about managing post-operative pain effectively and safely. This includes minimizing opioid use due to risks of addiction, side effects, and prolonged recovery. The availability of long-acting non-opioid analgesics like EXPAREL aims to address these patient needs by providing sustained pain relief and potentially reducing reliance on opioids [3].
---
Sources:
1. DrugPatentWatch.com, accessed November 26, 2023.
2. Pacira Biosciences, Inc. v. Mylan Pharmaceuticals Inc., et al. (D. Del. 2023).
3. EXPAREL prescribing information.
4. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.